Fig. 1: Trial profile. | Nature Communications

Fig. 1: Trial profile.

From: Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO)

Fig. 1: Trial profile.The alternative text for this image may have been generated using AI.

aOf the six patients who did not complete neoadjuvant treatment, three withdrew consent, one discontinued due to physical condition, one due to medication unavailability, and one due to financial reasons. bOf the 10 patients who did not complete neoadjuvant treatment, nine discontinued due to adverse events, and one due to medication unavailability. ICT neoadjuvant immunochemotherapy, CRT neoadjuvant chemoradiotherapy.

Back to article page